Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Disease × Pluvicto × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 38 Prostatic Diseases 3 Metastatic Castration-resistant Prostate Cancer 3 Urogenital Neoplasms 2 Neoplasms by Site 2 Neoplasms 2 Kidney Neoplasms 2 Genital Neoplasms, Male 2 Thrombocytopenia 1 Renal Insufficiency 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer Metastatic 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1 Male Urogenital Diseases 1 Liver Neoplasms 1 Glioma 1 Glioblastoma 1 Genital Diseases, Male 1 Disease 1 Cytopenia 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Astrocytoma 1 Anemia 1

Interventions

Magnetic Resonance Spectroscopy 6 Mammography 4 Dexamethasone 4 Cyclophosphamide 4 Colonoscopy 4 Blood Specimen Collection 4 Tomography, X-Ray Computed 3 Prednisone 3 Positron Emission Tomography Computed Tomography 3 Melphalan 3 Lenalidomide 3 weifuchun 2 pembrolizumab 2 fluciclovine F-18 2 daratumumab 2 Surveys and Questionnaires 2 Preoperative Exercise 2 Positron-Emission Tomography 2 Methods 2 Magnetic Resonance Imaging 2 Injections 2 Gemcitabine 2 Cytarabine 2 Control Groups 2 Biopsy, Fine-Needle 2 Biopsy 2 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2 vistusertib 1 venetoclax 1 tivozanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07054346 2025-12-01

LUTACT

University of California, San Francisco

Phase 1 Recruiting

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡